Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Peginterferon alfa-2b Clear all
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Study of PEG-Intron for Plexiform Neurofibromas

NCT00396019
View directory record Official record
Conditions
Plexiform Neurofibroma
Interventions
PEG-Intron
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Months to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

NCT00303290
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Peg Interferon Alpha 2b (Peg Intron), Ara-C (cytosine arabinoside)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

NCT00047879
View directory record Official record
Conditions
Glioma
Interventions
PEG-interferon alfa-2b, Thalidomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

NCT01964300
View directory record Official record
Conditions
Childhood Craniopharyngioma
Interventions
peginterferon alfa-2b, laboratory biomarker analysis
Biological · Other
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
18 Months to 25 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 1 Interventional

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00701298
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
peginterferon alfa-2b, decitabine, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

NCT02218164
View directory record Official record
Conditions
Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions
Pegylated Interferon alpha-2b, Capecitabine, 5-FU
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

NCT01935089
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

NCT00415857
View directory record Official record
Conditions
Leukemia
Interventions
Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma

NCT00006039
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer
Interventions
pegylated interferon alfa
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 1 Interventional

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

NCT00277758
View directory record Official record
Conditions
Hepatitis C
Interventions
Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

NCT00573378
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
PEG-IFN-a2b
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 1 Interventional Results available

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

NCT02948426
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Autologous Monocytes + ACTIMMUNE + SYLATRON
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

NCT00090870
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, GM-CSF, thalidomide
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

NCT00050531
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 27, 2026, 4:35 PM EDT
Terminated Phase 4 Interventional Results available

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

NCT01443923
View directory record Official record
Conditions
Hepatitis, HIV/AIDS
Interventions
Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

NCT00006325
View directory record Official record
Conditions
HIV Infections
Interventions
Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

NCT00248339
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Results available

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

NCT01405027
View directory record Official record
Conditions
Chronic Hepatitis C, Genotype 1
Interventions
Educational Intervention, Patient education and management skills training
Procedure · Other
Lead sponsor
Chronic Liver Disease Foundation
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

NCT00015652
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Aldesleukin, Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Results available

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

NCT00087646
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 27, 2026, 4:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

NCT01295515
View directory record Official record
Conditions
HIV Infection
Interventions
Pegylated Interferon Alpha 2b (PEGINTRON)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 27, 2026, 4:35 PM EDT